Andrew J. Armstrong, MD, MSc
- Medicine / Medicine - Oncology
- Surgery / Vascular
Address
DUMC 102002
Durham, NC 27710
Appointment Telephone
919-668-8108, option 1
Office Telephone
919-668-4667
Fax Telephone
919-668-7117
- MD, University of Virginia School of Medicine, 2000
- Internal Medicine, Hospital of the University of Pennsylvania, 2000-2003
- Medical Oncology, Johns Hopkins Hospital (Maryland), 2003-2006
- MSc, Clinical Investigation, Johns Hopkins School of Public Health (Maryland), 2007
Clinical Interests
Drug development and novel strategies for the treatment and management of advanced prostate cancer and other GU malignancies; targeted therapy; mTOR/Akt pathway inhibitor; prognostic and surrogate models in GU malignancies; perioperative biologic therapeutics; circulating tumor-cell biology
Research Interests
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Active Biotech
- Amgen, Inc.
- Analysis Group Inc.
- Bristol-Myers Squibb
- CR Bard, Inc.
- Decision Resources, Inc.
- Dendreon Corporation
- Easton Associates
- Gerson Lehrman Group, Inc.
- GlaxoSmithKline
- Guidepoint Clinical
- Imclone Systems Incorporated
- Johnson & Johnson
- Kohl's Corporation
- Leerink Swann and Company
- Medivation, Inc.
- Pfizer Inc.
- Sanofi-Aventis
- UBM Medica
- Wyeth (Pfizer)
Representative Publications
Armstrong AJ, Febbo PG, George DJ, Moul J. Systemic strategies for prostate cancer. Minerva Urol Nefrol. 2007 Mar;59(1):11-25.
(2007)
Abstract
Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 1;25(25):3965-70.
(2007)
Abstract
Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. Clin Cancer Res. 2007 Nov 1;13(21):6396-403.
(2007)
Abstract
Mendiratta P, Armstrong AJ, George DJ. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol. 2007;9 Suppl 1:S9-S19.
(2007)
Abstract
Srinivasan R, Armstrong AJ, Dahut W, George DJ. Anti-angiogenic therapy in renal cell cancer. BJU Int. 2007 May;99(5 Pt B):1296-300.
(2007)
Abstract
Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol. 2006 May;16(3):138-45.
(2006)
Abstract
Armstrong AJ, Eisenberger M. Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture? Nat Clin Pract Urol. 2006 May;3(5):246-7.
(2006)
Abstract
Armstrong AJ, Carducci MA. Advanced prostate cancer: the future. Can J Urol. 2005 Jun;12 Suppl 2:42-7.
(2005)
Abstract
Armstrong AJ, Carducci MA. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Curr Oncol Rep. 2005 May;7(3):220-7.
(2005)
Abstract
Armstrong AJ, Carducci MA. Novel therapeutic approaches to advanced prostate cancer. Clin Adv Hematol Oncol. 2005 Apr;3(4):271-82.
(2005)
Abstract
Nightingale RW, Camacho DL, Armstrong AJ, Robinette JJ, Myers BS. Inertial properties and loading rates affect buckling modes and injury mechanisms in the cervical spine. J Biomech. 2000 Feb;33(2):191-7.
(2000)
Abstract
Fukasawa K, Zhou R, Matten WT, Armstrong AJ, Daar I, Oskarsson M, Sathyanarayana BK, Maclvor L, Wood TG, Vande Woude GF. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding. Oncogene. 1995 Oct 19;11(8):1447-57.
(1995)
Abstract
